BKBettina Kempkes

Bettina Kempkes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bettina Kempkes has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Kristina Grabušić

    Department of Biotechnology, University of Rijeka, Rijeka, Croatia

    3 shared publications
  • Sabine Maier

    GSF – National Research Center for Environment and Health, Institute of Clinical Molecular Biology, Marchioninistr. 25, D-81377 Munich, Germany

    3 shared publications
  • Andrea Hartmann

    GSF – National Research Center for Environment and Health, Institute of Clinical Molecular Biology, Marchioninistr. 25, D-81377 Munich, Germany

    2 shared publications
  • Anja Mantik

    GSF – National Research Center for Environment and Health, Institute of Clinical Molecular Biology, Marchioninistr. 25, D-81377 Munich, Germany

    2 shared publications
  • Dirk Eick

    Institute of Clinical Molecular Biology and Tumor Genetics, GSF‐Research Center for Environment and Health, Munich, Germany

    2 shared publications
  • Elisabeth Dumont

    Institute of Clinical Molecular Biology and Tumor Genetics, GSF‐Research Center for Environment and Health, Munich, Germany

    2 shared publications

Latest Publications

  • Open Access

    The CR4 region of EBNA2 confers viability of Epstein–Barr virus-transformed B cells by CBF1-independent signalling

    by Kristina Grabusic, Sabine Maier, Andrea Hartmann, Anja Mantik, Wolfgang Hammerschmidt, Bettina Kempkes

    The Epstein–Barr virus (EBV) nuclear antigen 2 (EBNA2) gene product is the key regulator of the latent genes of EBV and essential for EBV-mediated transformation of human primary B cells. Viral mutants were constructed carrying a deletion of the EBNA2 conserved region 4 (CR4). Primary resting B cells infected with the ΔCR4-EBNA2 mutant virus were dramatically impaired for B cell transformation. Lymphoblastoid cell lines (LCLs) established with this mutant EBV revealed a prolonged population doubling time when cells were cultivated at low cell densities, which are not critical for wild-type-infected cells. Low-level spontaneous cell death occurred when the cells were cultivated at suboptimal cell densities. The phenotype of B cells and LCLs infected with the ΔCR4-EBNA2 mutant virus indicated that the CR4 region of EBNA2 specifically contributes to the viability of the cells rather than affecting cell division rates.


  • Cellular Target Genes of Epstein-Barr Virus Nuclear Antigen 2

    by Sabine Maier, Gabriele Staffler, Andrea Hartmann, Julia Höck, Karen Henning, Kristina Grabusic, Reinhard Mailhammer, Reinhard Hoffmann, Matthias Wilmanns, Roland Lang, et al.

    Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA-2) is a key determinant in the EBV-driven B-cell growth transformation process. By activating an array of viral and cellular target genes, EBNA-2 initiates a cascade of events which ultimately cause cell cycle entry and the proliferation of the infected B cell. In order to identify cellular target genes that respond to EBNA-2 in the absence of other viral factors, we have performed a comprehensive search for EBNA-2 target genes in two EBV-negative B-cell lines. This screen identified 311 EBNA-2-induced and 239 EBNA-2-repressed genes that were significantly regulated in either one or both cell lines. The activation of most of these genes had not previously been attributed to EBNA-2 function and will be relevant for the identification of EBNA-2-specific contributions to EBV-associated malignancies. The diverse spectrum of EBNA-2 target genes described in this study reflects the broad spectrum of EBNA-2 functions involved in virus-host interactions, including cell signaling molecules, adapters, genes involved in cell cycle regulation, and chemokines.


  • A Somatic Knockout of CBF1 in a Human B-Cell Line Reveals that Induction of CD21 and CCR7 by EBNA-2 Is Strictly CBF1 Dependent and that Downregulation of Immunoglobulin M Is Partially CBF1 Independent

    by Sabine Maier, Maja Santak, Anja Mantik, Kristina Grabusic, Elisabeth Kremmer, Wolfgang Hammerschmidt, Bettina Kempkes

    CBF1 is a cellular highly conserved DNA binding factor that is ubiquitously expressed in all tissues and acts as a repressor of cellular genes. In Epstein-Barr virus growth-transformed B-cell lines, CBF1 serves as a central DNA adaptor molecule for several viral proteins, including the viral transactivator Epstein-Barr virus nuclear antigen 2 (EBNA-2). EBNA-2 binds to CBF1 and thereby gains access to regulatory regions of target genes and activates transcription. We have inactivated the CBF1 gene by homologous recombination in the human B-cell line DG75 and characterized changes in cellular gene expression patterns upon loss of CBF1 and activation of EBNA-2. CBF1-negative DG75 cells were viable and proliferated at wild-type rates. Loss of CBF1 was not sufficient to release repression of the previously described EBNA-2 target genes CD21 or CCR7, whereas induction of both target genes by EBNA-2 required CBF1. In contrast, repression of immunoglobulin M by EBNA-2 was mainly CBF1 independent. CBF1-negative DG75 B cells thus provide an excellent tool to dissect CBF1-dependent and -independent functions exerted by the EBNA-2 protein in future studies.


  • Epstein‐Barr virus antagonizes the antiproliferative activity of transforming growth factor‐β but does not abolish its signaling

    by Manuela Horndasch, Eva E. Raschke, Guido Bommer, Marino Schuhmacher, Elisabeth Dumont, Conny Kuklik‐Roos, Dirk Eick, Bettina Kempkes

    TGF‐β induces apoptosis and inhibits the proliferation of EBV‐negative B‐lymphoma cell lines. In contrast, EBV‐immortalized B cells are resistant to both the proapoptotic and the antiproliferative activities of TGF‐β. We have generated a lymphoblastoid cell line, in which we can switch on and off the EBV‐specific transcriptional program driven by EBNA2. When these cells express the EBNA2‐driven phenotype, they are resistant to TGF‐β‐mediated growth arrest. We used this cell line to readdress the question of how EBV can overcome the antiproliferative TGF‐β activity. We show here that EBV‐driven cells remain TGF‐β‐responsive since TGF‐β target genes are readily induced. Thus, EBV can overcome TGF‐β‐mediated growth arrest without interfering with the core machinery of the TGF‐β signaling pathway, which links ligand binding to the induction of TGF‐β target genes.


  • Open Access

    Mutational analysis of the J recombination signal sequence binding protein (RBP‐J)/Epstein–Barr virus nuclear antigen 2 (EBNA2) and RBP‐J/Notch interaction

    by Klaus Peter Fuchs, Guido Bommer, Elisabeth Dumont, Barbara Christoph, Marc Vidal, Elisabeth Kremmer, Bettina Kempkes

    Epstein–Barr virus nuclear antigen 2 (EBNA2) and the Notch protein both function within the nucleus as transcriptional adaptor proteins. EBNA2 plays a key role during the immortalization of primary B‐cells by Epstein–Barr virus (EBV). Notch proteins are involved in lymphomagenesis as well as in multiple cell fate decisions during tissue differentiation and development. Both, EBNA2 and Notch interact with the DNA binding protein RBP‐J and thereby gain access to the promoter of their target genes. In order to identify regions within the J recombination signal sequence binding protein (RBP‐J), that are relevant for either the Notch or the EBNA2 interaction, we have performed a mutational analysis of RBP‐J. A library of RBP‐J mutants was screened by a reverse two‐hybrid system for alleles that fail to bind to either EBNA2 or Notch. The sequence analysis of these alleles reveals that a limited and particularly distinct number of amino‐acid positions are relevant for either interaction only. Given the important role of RBP‐J in B‐cell immortalization, the EBNA2/RBP‐J protein–protein interaction could be a candidate target for therapeutic intervention in EBV related diseases.


  • The Proto-Oncogene c- myc Is a Direct Target Gene of Epstein-Barr Virus Nuclear Antigen 2

    by Carmen Kaiser, Gerhard Laux, Dirk Eick, Nicola Jochner, Georg W. Bornkamm, Bettina Kempkes

    Epstein-Barr virus (EBV) infects and transforms primary B lymphocytes in vitro. Viral infection initiates the cell cycle entry of the resting B lymphocytes. The maintenance of proliferation in the infected cells is strictly dependent on functional EBNA2. We have recently developed a conditional immortalization system for EBV by rendering the function of EBNA2, and thus proliferation of the immortalized cells, dependent on estrogen. This cellular system was used to identify early events preceding induction of proliferation. We show that LMP1 and c- myc are directly activated by EBNA2, indicating that all cellular factors essential for induction of these genes by EBNA2 are present in the resting cells. In contrast, induction of the cell cycle regulators cyclin D2 and cdk4 are secondary events, which require de novo protein synthesis.